Exact Sciences Diagnostic Technology Found Effective in Detection of Cancer
Posted on: Friday, 16 November 2007, 12:00 CST
Exact Sciences has reported that the final results of the prospective, blinded, multi-center study of its version 2 technology for stool-based DNA screening for colorectal cancer were statistically consistent with the interim findings published earlier.
This study evaluated stool-based DNA (sDNA) in 82 patients with colorectal cancer and 363 colonoscopically normal individuals using Exact's version 2 technology. The study results were statistically consistent with the interim results and demonstrated 83% sensitivity for detecting cancers with a specificity of 82%. The interim study results from the first 40 cancer patients and 122 normal individuals reported 88% sDNA sensitivity for detecting cancer with a specificity of 82%.
Jeffrey Luber, president of Exact Sciences, said: "We are excited that these results are within the sensitivity range that was expected and we believe that they provide important validation of our version 2 technology."
Source: Datamonitor
Related Articles
- Canopus BioPharma Reports Positive Results From Cancer Vaccine Study
- Ikonisys Reports Positive Results From Cancer Detection Study
- Antisoma Reports Encouraging Results From Cancer Drug Study
- Innovive Reports Positive Results From Cancer Study
- Study Finds New Version of QIAGEN's HPV Test for Developing Countries Could Reduce Risk of Cervical Cancer By More Than Half When Combined With Appropriate Treatment
- Antisoma Reports Positive Results in Cancer Drug Study
- Protox Reports Promising Interim Results From Cancer Study
- Unilever Announces Third Quarter and Nine Month Results 2006 and Interim Dividends
- Cytokinetics Reports Poor Results From Cancer Study
- OrthoLogic Announces Results of Preliminary Interim Analysis of Phase 2b Clinical Trial of Chrysalin(R) (TP508) in Fracture Repair
 |
 |
User Comments (0)
RSS Feeds